Vor Biopharma Inc.
Vor Biopharma Inc. (VOR): 5 pipeline candidates · 2 upcoming catalysts · ~38 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
37.5 months
D/E -4.37 · 0% dilution
Lead: Approved
5 candidates
2 upcoming, next in ~928d
0 buys · 15 sells (180d)
A transparent, data-derived signal for Vor Biopharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$765.6M
Cash
$169.9M
Quarterly Burn
$38.2M
Runway
37.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| guselkumab | Approved |
| telitacicept | Phase 3 |
| trem-cel | Phase 2 |
| vadc45 | Preclinical |
| vcar33 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
76
Total value held
$518.0M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 5,404,998 | $96.4M |
| fcpm iii services b.v. | 4,117,354 | $73.5M |
| vanguard capital management llc | 2,866,560 | $51.1M |
| caligan partners lp | 1,925,066 | $34.3M |
| great point partners llc | 1,750,000 | $31.2M |
| fmr llc | 1,539,670 | $27.5M |
| marshall wace, llp | 1,153,276 | $20.6M |
| state street corp | 1,118,458 | $20.0M |
| nextbio capital management lp | 999,967 | $17.8M |
| blackrock, inc. | 794,759 | $14.2M |
Showing top 10 of 76 institutional holders of Vor Biopharma Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Vor Biopharma Inc.'s pipeline?
Vor Biopharma Inc. (VOR) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vor Biopharma Inc.'s lead drug candidate?
Vor Biopharma Inc.'s most advanced tracked candidate is guselkumab (Approved) for SLE, generalized MG and RA.
What is Vor Biopharma Inc.'s next catalyst?
Vor Biopharma Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to" — expected January 1, 2029.
What is Vor Biopharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vor Biopharma Inc. has approximately 37.5 months of cash runway.
What is Vor Biopharma Inc.'s market capitalization?
Vor Biopharma Inc.'s market capitalization is approximately $765.6M.
Get the full picture on Vor Biopharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.